LG3

About Stream Biomedical

Stream Biomedical is pioneering a regenerative therapeutic approach for acute brain injury and neurodegeneration with its lead biologic candidate, LG3. The therapy is designed to activate the brain's intrinsic repair systems by targeting multiple pathways involved in vascular integrity, inflammation, and neuronal recovery. Founded in 2018 and based in San Diego, the company is in the preclinical stage, with data supporting activity across multiple disease models. Its strategy addresses a significant unmet medical need across major neurological indications with a single, potentially disease-modifying agent.

About Stream Biomedical

Stream Biomedical is pioneering a regenerative therapeutic approach for acute brain injury and neurodegeneration with its lead biologic candidate, LG3. The therapy is designed to activate the brain's intrinsic repair systems by targeting multiple pathways involved in vascular integrity, inflammation, and neuronal recovery. Founded in 2018 and based in San Diego, the company is in the preclinical stage, with data supporting activity across multiple disease models. Its strategy addresses a significant unmet medical need across major neurological indications with a single, potentially disease-modifying agent.

About Stream Biomedical

Stream Biomedical is pioneering a regenerative therapeutic approach for acute brain injury and neurodegeneration with its lead biologic candidate, LG3. The therapy is designed to activate the brain's intrinsic repair systems by targeting multiple pathways involved in vascular integrity, inflammation, and neuronal recovery. Founded in 2018 and based in San Diego, the company is in the preclinical stage, with data supporting activity across multiple disease models. Its strategy addresses a significant unmet medical need across major neurological indications with a single, potentially disease-modifying agent.

Therapeutic Areas

Other Alzheimer's Disease & Related Dementias Drugs